PC3001 - ENT, Eyes and Respiratory Pharmacy

[Not offered in 2020]

Available to level 3 Bachelor of Pharmacy students.

Respiratory infections and eye problems are two common presentations in pharmacy practice. This subject builds upon knowledge of the anatomy, physiology, pathophysiology and pharmacotherapeutics in the areas of ophthalmology, ear, nose, throat, oral and respiratory pharmacy. The student will learn the pharmaceutics of formulations and dosage forms used to treat ear, nose, throat, eye, dental and respiratory conditions. An emphasis will be placed on the appropriate use of Pharmacy (S2) and Pharmacists Only (S3) medications; medical appliances; audiological conditions among indigenous populations; and the treatment and prevention of common disorders in these sensory/body systems.

Learning Outcomes

• describe the common clinical presentation and management of conditions of the ear, nose, throat, eye, mouth and respiratory system, especially the use of Pharmacy and Pharmacist Only medications and the use of medical devices in treating these conditions;
• develop an understanding of the principles of rational drug use in the treatment of these conditions;
• discuss the complexities of managing these conditions in rural and remote areas;
• outline the pathophysiology and therapeutics of respiratory conditions, including upper respiratory tract infections, acute and chronic conditions and preventative strategies;
• outline the pathophysiology and therapeutics of ophthalmological, nasal and aural conditions including audiological conditions found in Indigenous communities;
• describe the pharmaceutics of pharmaceutical formulations and dosage forms used in ophthalmology, ENT and respiratory conditions.

Subject Assessment

• Invigilated > End of semester exam - (60%)
• Oral exam (OSCE) - (25%)
• On-course Assessment - (15%).

Note: Minor variations might occur due to the continuous Subject quality improvement process, and in case of minor variation(s) in assessment details, the Subject Outline represents the latest official information.